Urinary tract infections lead to lost work time, emergency room visits and health care spending of $3.5 billion in the United States alone.
But because UTIs can occur with no apparent cause, and as effectiveness of antibiotics fades, treating them is also becoming less predictable.
Bacterial genetic targets for UTI genes
University of Michigan Medical School researchers have identified bacterial genes that help the infections spread, providing a potential new target for treating UTIs, a global public health concern mostly affecting women.
The research findings, published in December 2014 in Proceedings of the National Academy of Sciences, reveal the specific genes expressed by Escherichia coli (e.coli), the bacteria that most often causes UTIs in otherwise healthy people.
“The bacterium is becoming resistant to currently available antibiotics, making it imperative to develop new treatment and prevention strategies,” says senior study author Harry T. Mobley, PhD, the Frederick G Novy professor and chair of the Department of Microbiology and Immunology at the University of Michigan Health System.
“The next logical step is to identify and develop therapies that selectively block these UTI-specific genes.”
In the study of 42 women, 7.7 percent had infections that were resistant to ciprofloxacin, and 15.3 percent did not respond to trimethoprim/ sulfamethoxazole, two antibiotics commonly used for treatment.
The U-M team used genomic screening tools to take a deeper look at the mechanisms for infection. Rather than the expected virulence factor, the newly discovered E. coli-specific genes helped protect the bacterial species from the toxic effect of metal ions the body uses to fight infection.
Attacking this function, and other mechanisms that promote survival of the bacteria in the urinary tract, may be a strategy for new microbial agents, authors say. The Mobley research team is also part of a group working to identify a potential approach for a vaccine to prevent urinary tract infections.